Article ID Journal Published Year Pages File Type
8758090 European Journal of Internal Medicine 2018 7 Pages PDF
Abstract
Carbapenem-sparing regimens (e.g. piperacillin-tazobactam alone or with an aminoglycoside) could be empirically safely used in elderly patients at high risk of ESBL-EB BSI and for definitive treatment of ascertained cases if the primary site is the urinary tract, leaving early carbapenem use for cases at higher risk of death, such as those with pneumonia.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, , , , , , , , , , , ,